Payment overview · 2025
General Payments
$428.79
23 reported records · 6 companies
Healthcare provider profile · identity verified
Radhakrishna Kukkillaya, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOGAN, WV · NPI 1114981156
Verified facts
What the public records show
CMS Open Payments records show Radhakrishna Kukkillaya, M.D. received $428.79 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $207.26 | 48.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.26 | 23.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.64 | 14.4% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.60 | 4.8% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $19.26 | 4.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.77 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $428.79 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.75 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.66 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.19 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.19 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.64 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 832 | 192 |
| Alprazolam | Alprazolam | 812 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 702 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 164 |
| Potassium Chloride | Potassium Chloride | 677 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 667 | 141 |
| Omeprazole | Omeprazole | 651 | 164 |
| Metoprolol Succinate | Metoprolol Succinate | 640 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 536 | 135 |
| Furosemide | Furosemide | 534 | 133 |
| Pravastatin Sodium | Pravastatin Sodium | 531 | 126 |
| Metformin Hcl | Metformin Hcl | 528 | 130 |
| Metoprolol Tartrate | Metoprolol Tartrate | 450 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 448 | 109 |
| Ezetimibe | Ezetimibe | 427 | 98 |
| Losartan Potassium | Losartan Potassium | 395 | 112 |
| Gabapentin | Gabapentin | 376 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 344 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 36 |
| Glimepiride | Glimepiride | 295 | 81 |
| Famotidine | Famotidine | 290 | 69 |
| Montelukast Sodium | Montelukast Sodium | 285 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 61 |
| Eliquis | Apixaban | 248 | 62 |
| Simvastatin | Simvastatin | 248 | 64 |
| Lorazepam | Lorazepam | 240 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 230 | 63 |
| Alendronate Sodium | Alendronate Sodium | 228 | 60 |
| Ibuprofen | Ibuprofen | 227 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 35 |
| Azithromycin | Azithromycin | 178 | 151 |
| Donepezil Hcl | Donepezil Hcl | 168 | 39 |
| Sertraline Hcl | Sertraline Hcl | 166 | 38 |
| Prednisone | Prednisone | 158 | 106 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 153 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 147 | 58 |
| Carvedilol | Carvedilol | 143 | 37 |
| Allopurinol | Allopurinol | 142 | 34 |
| Tramadol Hcl | Tramadol Hcl | 142 | 58 |
| Torsemide | Torsemide | 139 | 37 |
| Celecoxib | Celecoxib | 137 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 42 |
| Diazepam | Diazepam | 134 | 19 |
| Jardiance | Empagliflozin | 134 | 32 |
| Trazodone Hcl | Trazodone Hcl | 126 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 87 |
| Fluconazole | Fluconazole | 124 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 33 |
| Pregabalin | Pregabalin | 119 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 118 | 26 |
| Clonidine Hcl | Clonidine Hcl | 110 | 34 |
| Ozempic | Semaglutide | 109 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 28 |
| Farxiga | Dapagliflozin Propanediol | 100 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 27 |
| Synthroid | Levothyroxine Sodium | 98 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 97 | 29 |
| Spironolactone | Spironolactone | 95 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 20 |
| Warfarin Sodium | Warfarin Sodium | 87 | 16 |
| Fenofibrate | Fenofibrate | 86 | 21 |
| Meloxicam | Meloxicam | 86 | 24 |
| Sucralfate | Sucralfate | 83 | 18 |
| Naproxen | Naproxen | 81 | 24 |
| Cefuroxime | Cefuroxime Axetil | 80 | 56 |
| Clonazepam | Clonazepam | 79 | 13 |
| Methocarbamol | Methocarbamol | 79 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 77 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 19 |
| Atenolol | Atenolol | 76 | 18 |
| Mounjaro | Tirzepatide | 75 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 75 | 13 |
| Nystatin | Nystatin | 74 | 38 |
| Cephalexin | Cephalexin | 72 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 18 |
| Temazepam | Temazepam | 71 | 12 |
| Vascepa | Icosapent Ethyl | 71 | 18 |
| Levofloxacin | Levofloxacin | 69 | 60 |
| Meclizine Hcl | Meclizine Hcl | 69 | 21 |
| Methylprednisolone | Methylprednisolone | 69 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 19 |
| Lovastatin | Lovastatin | 67 | 14 |
| Mirtazapine | Mirtazapine | 64 | 16 |
| Novolog Flexpen | Insulin Aspart | 63 | 23 |
| Linzess | Linaclotide | 62 | 14 |
| Januvia | Sitagliptin Phosphate | 61 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 60 | 21 |
| Buspirone Hcl | Buspirone Hcl | 59 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 17 |
| Amoxicillin | Amoxicillin | 56 | 49 |
| Ranolazine Er | Ranolazine | 56 | 12 |
| Glipizide | Glipizide | 55 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 30 |
| Nitroglycerin | Nitroglycerin | 53 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 16 |
| Ibu | Ibuprofen | 50 | 21 |
| Memantine Hcl | Memantine Hcl | 49 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 21 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 12 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 14 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 20 |
| Hydrocortisone | Hydrocortisone | 38 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 35 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | 11 |
| Mometasone Furoate | Mometasone Furoate | 33 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 16 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 24 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Famciclovir | Famciclovir | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Oxaprozin | Oxaprozin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $428.79 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 2, GEMTESA, LINZESS, OTEZLA, QULIPTA, REPATHA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error